Al-Janabi A - Search Results

1

Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.

Al-Janabi A, Martin P, Khan AR, Foulkes AC, Smith CH, Griffiths CEM, Morris AP, Eyre S, Warren RB; BSTOP Study Group and the BADBIR Study Group. Al-Janabi A, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1237-1246. doi: 10.1016/j.jaci.2023.07.011. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536512 Free article.

2

Pemphigus vulgaris: a rare cause of dysphagia.

Al-Janabi A, Greenfield S. Al-Janabi A, et al. BMJ Case Rep. 2015 Oct 22;2015:bcr2015212661. doi: 10.1136/bcr-2015-212661. BMJ Case Rep. 2015. PMID: 26494724 Free PMC article.

3

An evaluation of the SureID 23comp Human Identification Kit for kinship testing.

Alsafiah HM, Aljanabi AA, Hadi S, Alturayeif SS, Goodwin W. Alsafiah HM, et al. Sci Rep. 2019 Nov 14;9(1):16859. doi: 10.1038/s41598-019-52838-7. Sci Rep. 2019. PMID: 31727926 Free PMC article.

4

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Al-Janabi A, et al. Br J Dermatol. 2019 Jun;180(6):1348-1351. doi: 10.1111/bjd.17624. Epub 2019 Mar 27. Br J Dermatol. 2019. PMID: 30632140 Clinical Trial.

5

Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.

Al-Janabi A, Warren RB. Al-Janabi A, et al. Br J Dermatol. 2020 Aug;183(2):220-221. doi: 10.1111/bjd.18856. Epub 2020 Feb 13. Br J Dermatol. 2020. PMID: 31899817 No abstract available.

6

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. Al-Janabi A, et al. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1440-1448. doi: 10.1111/jdv.16246. Epub 2020 Feb 27. J Eur Acad Dermatol Venereol. 2020. PMID: 31997406 Review.

7

Update on risankizumab for the treatment of moderate to severe psoriasis.

Al-Janabi A, Warren RB. Al-Janabi A, et al. Expert Opin Biol Ther. 2020 Nov;20(11):1245-1251. doi: 10.1080/14712598.2020.1822813. Epub 2020 Sep 25. Expert Opin Biol Ther. 2020. PMID: 32933320 Review.

8

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre.

Kreeshan FC, Al-Janabi A, Warren RB, Hunter HJA. Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021 Feb;11(1):149-160. doi: 10.1007/s13555-020-00469-6. Epub 2020 Dec 14. Dermatol Ther (Heidelb). 2021. PMID: 33315229 Free PMC article.

9

Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.

Al-Janabi A, Littlewood Z, Griffiths CEM, Hunter HJA, Chinoy H, Moriarty C, Yiu ZZN, Warren RB. Al-Janabi A, et al. Br J Dermatol. 2021 Sep;185(3):646-648. doi: 10.1111/bjd.20479. Epub 2021 Jun 4. Br J Dermatol. 2021. PMID: 33982284 Free PMC article. No abstract available.

10

Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.

Ali Z, Matthews R, Al-Janabi A, Warren RB. Ali Z, et al. Expert Rev Clin Immunol. 2021 Oct;17(10):1073-1081. doi: 10.1080/1744666X.2021.1967748. Epub 2021 Aug 20. Expert Rev Clin Immunol. 2021. PMID: 34384327 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters